Chemocentryx (CCXI) Narrows Q3 Loss to 28c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Join SI Premium – FREE
Chemocentryx (NASDAQ: CCXI) reported Q3 EPS of ($0.28), versus ($2.06) reported last year. Revenue for the quarter came in at $1.13 million, versus $1.44 million reported last year.
For earnings history and earnings-related data on Chemocentryx (CCXI) click here.
For earnings history and earnings-related data on Chemocentryx (CCXI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransUnion (TRU) Tops Q3 EPS by 4c; Offers FY26 EPS Guidance
- Provident Financial Holdings (PROV) Misses Q1 EPS by 7c
- Nautilus Biotechnology, Inc. (NAUT) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
